BofA analyst Greg Harrison expects any acquisition of BridgeBio Phamra to be in the $3B-$4B range. The stock is trading higher today as reports of takeover interest continue to circulate while the company cancelled from an upcoming competitor investor conference, the analyst tells investors in a research note. The firm thinks BridgeBio has "multiple attractive assets" to large biotechs and pharmas. It keeps a Buy rating on the stock with an $18 price target, which represents a net present value of $2.9B.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BBIO:
- BridgeBio Pharma call volume above normal and directionally bullish
- Here’s Why Investors Are Excited About BridgeBio (NASDAQ:BBIO) Stock
- BridgeBio attracting bigger companies’ takeover interest, Bloomberg says
- BridgeBio announces first patient dosed in Phase 1 trial of BBP-398 with OPDIVO
- BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
